Phase 4
Completed N=70
Cannabinoids for Pain Control During Medical Abortion
Medical Abortion · Postoperative Pain
Source: ClinicalTrials.gov NCT03604341 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcomePrimary: Maximum Self-reported Pain Score on a Numeric Rating Scale — 7; 7 score on a scale
◆ Published Evidence
Emerging
9citations · ~2 / year
Cannabinoids for Pain Control During Medical Abortion: A Randomized Controlled Trial.
Summary
The objective of this study is to determine if a synthetic cannabis derivative, dronabinol, in addition to ibuprofen, decreases maximum pain scores compared to ibuprofen and placebo in women undergoing medical abortion. Results of this study will help providers counsel patients regarding cannabis use during medical abortion.
Linked Publications
-
Cannabinoids for Pain Control During Medical Abortion: A Randomized Controlled Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Self-reported Pain Score on a Numeric Rating Scale |
7; 7 | — |
Eligibility Criteria
Inclusion Criteria
- Aged 21 years or older
- Consented for elective medical abortion
- Pregnancy with intrauterine gestational sac up to 10 0/7 weeks, dated by ultrasound
- Able and willing to receive text messages via phone
- English speaking
- Able and willing to give informed consent and agree to the study terms
- Have assistance at home; no motor vehicle use while taking study medications
Exclusion Criteria
- Desires to continue pregnancy or currently breastfeeding
- Lack of access to cell phone and texting capabilities
- Prior participation in this study
- Early pregnancy failure
- Contraindications to the study medications: Marinol or marijuana derivatives, sesame oil, Ibuprofen
- Contraindications to medical abortion with Mifepristone or Misoprostol
- History of methadone, buprenorphine or heroin use within the last year
- History of a seizure disorder
- Used marijuana 5 or more days in the last week
- History of any adverse effects associated with prior use of recreational or medical marijuana products, or sensitivity/allergy to Marinol.
Data sourced from ClinicalTrials.gov (NCT03604341) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.